Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Recurrence 1Papillomavirus Infections 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Gliosarcoma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Sorafenib 42Bevacizumab 16Oxaliplatin 13Radiosurgery 10Gemcitabine 10Doxorubicin 10Capecitabine 10Leucovorin 9Hepatectomy 9Fluorouracil 9Cisplatin 9Radiofrequency Ablation 8Nivolumab 8pembrolizumab 7Drug Therapy 7Carboplatin 7Irinotecan 6Cryosurgery 6Talaporfin 5Mitomycin 5Everolimus 5Erlotinib Hydrochloride 5Electroporation 5spartalizumab 4Sunitinib 4Melphalan 4Ipilimumab 4Epirubicin 4Embolization, Therapeutic 4regorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Neoplasms × Receptor Protein-Tyrosine Kinases × Clear all
NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Biogen

Phase 1 Completed
40 enrolled
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡